FIG 1.

Maraviroc promotes HIV-1 latency reversal in resting CD4⁺ T cells. HIV-1 latency reversal was estimated by the number of copies per million of HIV-1 usRNA in resting CD4⁺ T cells from all patients as determined by nested qRT-PCR. (A) Individual changes in usRNA levels are shown for each study participant. (B) Expression of the number of copies of usRNA per million resting CD4⁺ T cells per day of the study. Significant changes between time points were determined using the Wilcoxon signed-rank test. Central lines indicate the median. (C) Expression of usRNA before, during, and after 10-day intensification of maraviroc in resting CD4⁺ T cells of the patients. Samples were stratified into the following groups: baseline (Pre-MVC); day 1, day 3, day 10 (On MVC); and day 28 (Post-MVC). Comparisons of expression of usRNA among the premaraviroc, on-maraviroc, and off-maraviroc time periods were also performed using the Wilcoxon signed-rank test. (D) Fold change in usRNA following maraviroc treatment in resting CD4⁺ T cells compared to baseline. The maximum fold change in usRNA during the study (dark gray bar) and the change at day 28 (light gray bar) are shown for resting CD4⁺ T cells, and the median (IQR) change is shown for all participants. The solid line indicates 1-fold change. MVC, maraviroc.